Senti Biosciences, an early clinical stage biotechnology company, reported a net loss of $11.2 million for the three months ended June 30, 2024, compared to a net loss of $18.7 million for the same period in 2023. The company's accumulated deficit as of June 30, 2024, was $267.7 million. Senti completed a strategic transaction with GeneFab, LLC, which provided additional capital and reduced longer-term operating expenses. The company is entitled to receive total consideration of $37.8 million before the end of 2025, with $18.9 million due at closing. Senti Biosciences has also entered into a collaboration with BlueRock, a subsidiary of Bayer, and has agreements with other related parties such as Seer, Inc. and GeneFab, LLC. The company's future plans include advancing its gene circuit platform technologies, continuing...Show More

Senti Biosciences, an early clinical stage biotechnology company, reported a net loss of $11.2 million for the three months ended June 30, 2024, compared to a net loss of $18.7 million for the same period in 2023. The company's accumulated deficit as of June 30, 2024, was $267.7 million. Senti completed a strategic transaction with GeneFab, LLC, which provided additional capital and reduced longer-term operating expenses. The company is entitled to receive total consideration of $37.8 million before the end of 2025, with $18.9 million due at closing. Senti Biosciences has also entered into a collaboration with BlueRock, a subsidiary of Bayer, and has agreements with other related parties such as Seer, Inc. and GeneFab, LLC. The company's future plans include advancing its gene circuit platform technologies, continuing preclinical and clinical development of product candidates, and exploring new partnerships and collaborations. Senti Biosciences has received a grant award of $8 million from the California Institute of Regenerative Medicine to support the clinical development of SENTI-202. The company's financial resources are not expected to be sufficient beyond twelve months from the date of the report, and substantial doubt exists about the company's ability to continue as a going concern without additional funding.